TMS for the treatment of auditory hallucinations
The Carlat Psychiatry Report, Volume 5, Number 5, May 2007
Topics: Brain Devices
James Ellison, MD, MPH
In the February issue of TCPR, we reported a recent FDA panel’s opinion that rTMS (repetitive transcranial magnetic stimulation) was relatively ineffective for treatment-resistant depression. The type of rTMS that has been tested for depression generally involves 10 Hz (ten pulses per second).
James Ellison, MD
Clinical Director, Geriatric Psychiatry Program, McLean Hospital Associate Professor of Psychiatry, Harvard Medical School
Dr. Ellison has disclosed that he is on the speaker’s bureaus of Pfizer, Inc., Wyeth, Inc., and Forest Laboratories, and has spoken about Aricept, Effexor XR, Lexapro, and Namenda. He has received between $5,000 and $20,000 over the last 12 months for these activities. He has also received research grant support, via McLean hospital, from GlaxoSmithKline for research on Avandia (rosiglitazone). Dr. Carlat has reviewed and edited the content of this interview to ensure a balanced and unbiased presentation.